PT  - JOURNAL ARTICLE
AU  - Auer, Matthias K.
AU  - Paizoni, Luisa
AU  - Neuner, Meike
AU  - Lottspeich, Christian
AU  - Schmidt, Heinrich
AU  - Bidlingmaier, Martin
AU  - Hawley, James
AU  - Keevil, Brian
AU  - Reisch, Nicole
TI  - Elevated 11-oxygenated androgens are not a major contributor to HPG-axis disturbances in adults with congenital adrenal hyperplasia due to 21-hydroxylase deficiency
AID  - 10.1101/2021.01.13.21249718
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.01.13.21249718
4099  - http://medrxiv.org/content/early/2021/01/15/2021.01.13.21249718.short
4100  - http://medrxiv.org/content/early/2021/01/15/2021.01.13.21249718.full
AB  - Context Hypothalamus-pituitary-gonadal (HPG)-axis disturbances are a common phenomenon in patients with classic congenital adrenal hyperplasia (CAH). 11-oxygenated androgens have been suggested to play a role in this context.Design Cross-sectional single center study including 89 patients (N=42 men, N=55 women) with classic CAH.Main Outcome Measures Independent predictors for hypogonadism in men and secondary amenorrhea in women with CAH with a special focus on 11-ketotestosterone (11KT) and 11β-hydroxyandrostenedione (11OHA4).Results Hypogonadotropic hypogonadism was present in 23% of men and 61% of those women currently not on contraceptives suffered from irregular menstrual cycles or amenorrhea. Testicular adrenal rest tumor (TART) was documented in 28% of men. While 11KT (3.5x) and 11OHA4 (5.7x) among other adrenal steroids were significantly elevated in men with hypogonadism, in stepwise logistic regression, the only significant independent predictor for hypogonadism were elevated 17-OHP levels (B = 0.006; p = 0.039). Although 11KT (5.2x) and 11OHA4 (3.7x) levels were also significantly higher in women with amenorrhea in comparison to those with a regular cycle, the only significant predictor for amenorrhea were elevated total testosterone levels (B = 1.806; p = 0.040). 11-oxygenated androgens were not different in those with TART and those without. Of note, there were no significant differences in 11OHA4 or 11KT between those with a regular cycle and those currently on hormonal contraceptives.Conclusions 11-oxygenated androgens do not seem to add additional information for explaining menstrual disturbances and hypogonadism in patients with CAH in comparison to established marker of disease control.HighlightsThe 11-oxygenated androgens 11-ketotestosterone and 11β-hydroxyandrostenedione are significantly elevated in men with CAH with hypogonadotropic hypogonadism and women with amenorrhea.Elevated 17-OHP levels in male patients and elevated testosterone levels in female patients are however the dominant predictor of HPG-axis disturbances.11-oxygenated androgens are not predictive for testicular adrenal rest tumors in men with CAH11-ketotestosterone and 11β-hydroxyandrostenedione levels do not seem to be influenced by intake of oral contraceptives.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the IFCAH grant 2013 to NR and by the Deutsche Forschungsgemeinschaft (Heisenberg Professorship 325768017 to NR and Projektnummer: 314061271-TRR205 to NR). The authors declare no competing interests. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical review board of the Ludwig-Maximilian-UniversitaetAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is can be provided by the corresponding author on reasonable request11KT11-ketotestosterone11OHA411β-hydroxyandrostenedione17-OHP17α-hydroxyprogesteroneACTHAdrenocorticotropic hormoneARAndrogen receptorCAHCongenital adrenal hyperplasiaCPACyproterone acetateDHEASDehydroepiandrosterone sulfateEREstrogen receptorFCFludrocortisoneFSHFollicle-stimulating hormoneGCGlucocorticoid(s)GnRHGonadotropin releasing hormoneHCHydrocortisoneHPGHypothalamus-pituitary-gonadalLHLuteinizing hormonePRProgesterone receptorSERMSelective estrogen receptor modulatorSHBGSex hormone binding globulinSVSimply virilizingSWSalt-wastingTARTTesticular adrenal rest tumor